Blog Posts

Amer Zeidan Presents ASCERTAIN-V Study on All-Oral Therapy for AML at ASCO25

Amer Zeidan/yalemedicine.org

Jun 13, 2025, 06:48

Amer Zeidan Presents ASCERTAIN-V Study on All-Oral Therapy for AML at ASCO25

Amer Zeidan, Associate Professor of Medicine (Hematology) at the Yale University, posted on X:

“What a pleasure to present and usher a new era in AML with total oral therapy through ASCERTAIN-V study at ASCO25 All-Oral Regimen of Decitabine-Cedazuridine plus Venetoclax in Newly Diagnosed AML Ineligible for Intensive Induction Chemo.”

Read Further.

More about ASCO 2025 Symposium on OncoDaily.

Amer Zeidan AML ASCERTAIN-V study ASCO25 cancer OncoDaily Oncology

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...

World’s Nicest Judge Frank Caprio Dies at 88 After Brave Battle with Pancreatic Cancer

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023

Facebook

Youtube

Insight

Aug 21, 2025, 13:21

Harpreet Singh: FDA’s New Draft Guidance on Radiopharmaceutical Dosing Is Here

Voices

Aug 21, 2025, 13:19

Miriam Mutebi: Why We Need to Expand Research in Palliative and Supportive Care

Insight

Aug 21, 2025, 13:16

Javier Martin-Broto: Collaborative Study Supports Mifamurtide Use in Osteosarcoma Treatment

Voices

Aug 21, 2025, 12:57

How Cancer-Induced Nerve Injury Contributes to Immunotherapy Resistance - MD Anderson Cancer Center

Voices

Aug 21, 2025, 12:34

Nirmala Bhoo Pathy: First-Ever Workshop on Patient and Financial Navigation

Immune Oncology

Aug 21, 2025, 12:34

PPP2R1A Mutations as a Biomarker in Immunotherapy: New Insights from Ovarian Clear Cell Carcinoma

Insight

Aug 21, 2025, 12:31

Alisher Kahharov: Uzbekistan's First National Breast Cancer Guideline - A Collaborative Effort with WHO and Georgian Experts

Radiotherapy

Aug 21, 2025, 12:31

New RT Paper Alert: Novel NOVEMBER Trial Puts 9-Day Breast Cancer Radiation Schedule to the Test

Opinion

Aug 21, 2025, 12:03

UICC Enhances Cancer Care with Nutrition and Psycho-Oncology Support

Voices

Aug 21, 2025, 11:40

FDA has Granted Full Market Approval for Papzimeos - NIH

Insight

Aug 21, 2025, 11:16

Kefah Mokbel: TAD Proven Safe with Effective Long-Term Outcomes for Breast Cancer Patients

Voices

Aug 21, 2025, 11:15

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...